Exocrine Pancreatic Insufficiency Treatment Market Report and Forecast 2024-2032

Exocrine Pancreatic Insufficiency Treatment Market Size

The exocrine pancreatic insufficiency treatment market was valued at USD 4.22 billion in 2023, driven by the increasing cases of cystic fibrosis, which commonly develop EPI due to thickened secretions that obstruct the pancreatic ducts across the 8 major markets. The market is expected to grow at a CAGR of 8.27% during the forecast period of 2024-2032, with the values likely to reach USD 8.63 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Exocrine Pancreatic Insufficiency Treatment Market Outlook

• The incidence of chronic pancreatitis, a leading cause of EPI, is rising due to factors such as alcohol abuse, smoking, and obesity, which is driving the growth of the market. According to an article pu blished by National Institute of Health, the annual incidence of acute pancreatitis (AP) is estimated to be approximately 40/100,000 persons in the United States, resulting in over 130,000 new cases per year.

• Increasing incidence of pancreatic cancer, often associated with EPI due to tumor-induced obstruction of pancreatic ducts is expected to further fuel the market growth.

• The ongoing research into new therapeutic targets and formulations for exocrine pancreatic insufficiency treatment drives market expansion. Companies are leveraging technological advancements in biotechnology and drug delivery systems to enhance product offerings results into market expansion.

Exocrine Pancreatic Insufficiency Treatment Market Overview

Exocrine pancreatic insufficiency (EPI) is a condition characterized by the inability of the pancreas to produce enough digestive enzymes to properly digest food. The treatment includes PERT, which involves taking pancreatic enzyme supplements with meals and snacks to replace the deficient enzymes. The enzyme supplements typically contain lipase, protease, and amylase to aid in the digestion of fats, proteins, and carbohydrates.

EPI is primarily caused by conditions that affect pancreatic function, such as chronic pancreatitis, cystic fibrosis, pancreatic cancer, and pancreatic surgery. The prevalence of these underlying conditions contributes to the growing demand for EPI treatment market.

The pharmaceutical companies are focusing on developing advanced formulations of pancreatic enzymes to improve stability, efficacy, and patient compliance. These innovations aim to optimize treatment outcomes and enhance patient satisfaction, which is expected to drive the market growth.

Exocrine Pancreatic Insufficiency Treatment Market Growth Drivers

Increasing Incidence and Prevalence of Underlying Conditions

Chronic pancreatitis is a significant cause of EPI, which is increasingly diagnosed due to rising cases linked to alcohol abuse, obesity, and other factors. This genetic condition affects pancreatic function, leading to EPI in a substantial number of patients. According to an article published by NCB I, chronic pancreatitis is the most common pancreatic disease associated with EPI.

Other conditions like pancreatic cancer and surgical interventions on the pancreas can impair its ability to produce digestive enzymes, necessitating EPI treatment. According to an article published by NCB I, pancreatic surgery alters digestive anatomy, the correct mixing of food, bile, and pancreatic enzymes and reduces the pancreatic volume. Different procedures are associated with different degrees of EPI. The growing number of individuals diagnosed with chronic pancreatitis directly expands the pool of patients at risk of developing EPI, thereby increasing the demand for its treatment market.

Technological Advancements in Treatment Options is Expected to Propel Exocrine Pancreatic Insufficiency Treatment Market Demand

The technological advancements in treatment options play a crucial role in driving the growth and development of the treatment market. The technological innovations enable the development of more effective formulations of pancreatic enzymes, including lipase, protease, and amylase. These formulations are designed to better mimic natural pancreatic enzyme activity, thereby improving digestion and nutrient absorption in patients with EPI. Pancreatic Enzyme Replacement Therapy (PERT) remains the mainstay of EPI treatment, with ongoing advancements in enzyme formulations, delivery systems, and dosing regimens to enhance efficacy and patient compliance.

The advancement in treatment includes other alternative therapies, exploration of adjunctive therapies, such as proton pump inhibitors (PPIs), dietary modifications, and nutritional supplements, provides additional treatment options tailored to patient needs. This innovation leads to increase in market demand.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Exocrine Pancreatic Insufficiency Treatment Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

Exocrine Pancreatic Insufficiency Treatment Market Segmentation

Market Breakup by Treatment

• Pancreatic Enzyme Replacement Therapy (PERT)

• Nutritional Therapy (Dietary Supplements)

• Others

Market Breakup by Indication

• Abdominal Pain

• Constipation

• Diarrhea

• Fatty Stools

• Weight Loss

• Others

Market Breakup by End User

• Hospitals

• Homecare

• Specialty Centers

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• India

Exocrine Pancreatic Insufficiency Treatment Market Share

Market Segmentation Based on Treatment is Anticipated to Witness Substantial Growth

By treatment, the market is segmented into pancreatic enzyme replacement therapy (PERT), nutritional therapy (dietary supplements) and others. The pancreatic enzyme replacement therapy (PERT) segment is expected to dominate the market because it is the most recommended treatment. It helps in managing EPI symptoms by replacing the deficient pancreatic enzymes (lipase, protease, amylase) required for proper digestion of fats, proteins, and carbohydrates.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Exocrine Pancreatic Insufficiency Treatment Market Analysis by Region

Regionally, the market report offers an insight into the United States, EU-4 and the United Kingdom, Germany, France, Italy, Spain, United Kingdom, Japan, and India. The United States, having a robust healthcare infrastructure and a strong presence of prominent pharmaceutical companies, is estimated to hold a high market value. The robust research and development activities in pharmaceutical and biotechnology sectors, leading to continuous advancements in pancreatic enzyme replacement therapy (PERT) formulations, driving the regional demand.

Germany holds a high exocrine pancreatic insufficiency treatment market value as the region boasts a well-developed healthcare system with robust diagnostic capabilities and access to specialized care, facilitating early detection and management of EPI.

Additionally, Japan is expected to witness substantial market growth as the region has made significant progress in raising awareness among healthcare providers about gastrointestinal disorders, including EPI. This has led to improved diagnosis and management of the condition and thus driving the market demand.

Leading Players in the Exocrine Pancreatic Insufficiency Treatment Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, fundings and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

AbbVie Inc.

AbbVie Inc., a prominent pharmaceutical company, has been involved in the treatment of exocrine pancreatic insufficiency (EPI) through its development and marketing of pancreatic enzyme replacement therapy (PERT) products.

Johnson & Johnson Services, Inc.

Johnson & Johnson Services, Inc., as a global pharmaceutical company focuses on several therapeutic areas such as pharmaceuticals, generics, eye care, and oncology, among others, including EPI.

Other key players in the market include Nordmark Arzneimittel GmbH and Co. KG, Digestive Care, Inc., Cilian AG, Chiesi Farmaceutici S.p.A., Anthera Pharmaceuticals, Inc., and Aptalis Pharma Inc. among others.

Key Highlights of the Report

Key Questions Answered in the Exocrine Pancreatic Insufficiency Treatment Market Report

• What was the exocrine pancreatic insufficiency treatment market value in 2023?
• What is the exocrine pancreatic insufficiency treatment market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on treatment?
• What is market segmentation based on indication?
• What is market segmentation based on end user?
• What are the major factors aiding the exocrine pancreatic insufficiency treatment market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the major trends influencing the market? 
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How does the growing cases of chronic pancreatis affect the market landscape?
• How does the clinical trials impact the market size?
• Who are the key players involved in the exocrine pancreatic insufficiency treatment market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?